TRDA vs TRVI

Entrada Therapeutics, Inc. vs Trevi Therapeutics, Inc. — Valuation Comparison 2026

TRDA

Biotechnology
Entrada Therapeutics, Inc.
Quality
4.8
out of 10
Value Trap
24
SAFE
Price
$6.82
Last close
Models
9/13
Active
VS

TRVI

Biotechnology
Trevi Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
30
LOW
Price
$14.45
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TRDA Fair ValueTRDA Upside TRVI Fair ValueTRVI Upside
Bayesian DCF Intrinsic $1.83 -73.2% $4.39 -69.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.86 -87.4% $0.40 -97.3%
Dynamic NAV Asset-Based $6.50 -4.7% $1.06 -92.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRDA vs TRVI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRDA vs TRVI — Which Stock Is More Undervalued?

TRDA scores higher with a 4.8/10 quality rating vs TRVI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Entrada Therapeutics, Inc. (TRDA) and Trevi Therapeutics, Inc. (TRVI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRDA currently trades at $6.82 with a QOC of 4.8/10, while TRVI trades at $14.45 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).